EXTENDED RELEASE UPADACITINIB FORMULATIONS

ABSTRACT

The disclosure describes extended release solid dosage forms comprising upadacitinib, or a pharmaceutically acceptable salt thereof, wherein the solid dosage form provides pH-independent drug release. In particular, the disclosure describes extended release solid dosage forms comprising upadacitinib, or a pharmaceutically acceptable salt thereof, at least one pH–dependent polymer and at least one release control material.

[FIG. 1A]